Small Extracellular Vesicles and Insulin Action
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: People with Metabolically Unhealthy Obesity - Low Calorie Diet.
- Who it may be relevant to
- Registry conditions: Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign. Basic parameters: 25 years — 55 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Small Extracellular Vesicles From Adipose Tissue on Insulin Action
Overview
The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.
Detailed description
Insulin resistance is commonly associated with obesity and is a major contributor to the development of obesity-related metabolic diseases, including nonalcoholic fatty liver disease, the metabolic syndrome, and type 2 diabetes (T2D). Most persons with obesity are "metabolically unhealthy" (MUO), often defined by having insulin resistance and the metabolic syndrome. However, a subset of people with obesity are metabolically healthy (MHO) and protected from the adverse metabolic effects of excess adiposity. The mechanisms that determine the differences in metabolic health between people with MUO and MHO are not unclear. This project will examine the effects of plasma and adipose tissue small extracellular vesicles (sEVs) on multi-organ insulin action. The investigators will isolate sEVs from subcutaneous abdominal adipose tissue biopsies and blood samples obtained from human participants with MHO, MUO or who are metabolically healthy and lean (MHL) and examine the effects of these sEVs on insulin resistance in muscle, liver and fat cells in culture and on multi-organ insulin sensitivity in lean and obese mice. The investigators will also identify differences in the potential bioactive molecules, namely miRNA and bioactive lipids, that are carried by sEVs. The results from this study will help determine whether plasma or adipose tissue sEVs in people who are MHL, MHO, or MUO are involved in regulating liver, muscle and adipose tissue insulin sensitivity. These results could identify novel pathways that regulate metabolic health in people and provide the foundation for exploring the potential of sEVs as a therapeutic target to prevent and treat the metabolic complications of obesity.
Interventions
- Behavioral People with Metabolically Unhealthy Obesity - Low Calorie Diet
Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
Primary outcome measures
- Effect of exosomes on insulin sensitivity in cultured cells [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).]
- Change in the effect of exosomes on insulin sensitivity [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
Secondary outcome measures (12)
- Differences in the content of microRNAs within exosomes obtained from plasma and adipose tissue [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).]
- Differences in the content of lipids within exosomes obtained from plasma and adipose tissue [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).]
- Changes in the content of microRNAs within exosomes obtained from plasma and adipose tissue [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
- Changes in the content of lipids within exosomes obtained from plasma and adipose tissue [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
- Insulin sensitivity [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).]
- Change in insulin sensitivity [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
- Fat mass and fat free mass [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).]
- Change in fat mass and fat free mass [Time frame: Before and after 10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
- Abdominal adipose tissue volumes [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).]
- Change in abdominal adipose tissue volumes [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
- Intra-hepatic triglyceride content [Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).]
- Change in intra-hepatic triglyceride content [Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity]
Eligibility criteria
Inclusion criteria
- Metabolically healthy lean subjects must have a BMI ≥18.5 and ≤24.9 kg/m²; Subjects with obesity must have a BMI ≥30.0 and ≤50.0 kg/m²
- Metabolically healthy lean and people with metabolically healthy obesity must have intrahepatic triglyceride (IHTG) content ≤5%; fasting plasma glucose concentration <100 mg/dl, 2-hr oral glucose tolerance plasma glucose concentration <140 mg/dl, hemoglobin A 1C (HbA1c) ≤5.6% and HOMA-IR <2.5.
- People with metabolically unhealthy obesity must have intrahepatic triglyceride (IHTG) content ≥5.6%; HOMA-IR ≥2.5, and HbA1c 5.7%-6.4%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg/dl.
Exclusion criteria
- History of diabetes, liver disease other than NAFLD or other serious diseases,
- Consume excessive amounts of alcohol (>21 units/week for men and >14 units/week for women),
- Take medications that could affect the study outcome measures, engage in regular exercise (>120 min/week),
- Are pregnant or lactating
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
United States · 1 center
- Washington University School of Medicine — St Louis
Identifiers
NCT: NCT05933707 · 202005117